Lipidoids: A Combinatorial Approach to siRNA Delivery
暂无分享,去创建一个
[1] D. Scherman,et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[2] Michael S. Goldberg,et al. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway , 2007, Nature.
[3] Phillip A Sharp,et al. Promoting Convergence in Biomedical Science , 2011, Science.
[4] V. Hornung,et al. siRNA and isRNA: two edges of one sword. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[5] M. G. Finn,et al. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. , 2001, Angewandte Chemie.
[6] Michael S. Goldberg,et al. Drug Delivery–mediated Control of RNA Immunostimulation , 2009, Molecular Therapy.
[7] M. Manoharan,et al. RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.
[8] J. Heyes,et al. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[9] Matthias John,et al. RNAi-mediated gene silencing in non-human primates , 2006, Nature.
[10] C. Bertozzi,et al. A "traceless" Staudinger ligation for the chemoselective synthesis of amide bonds. , 2000, Organic letters.
[11] K. Heeg,et al. Modifications in Small Interfering RNA That Separate Immunostimulation from RNA Interference1 , 2008, The Journal of Immunology.
[12] Michael S. Goldberg,et al. Assessing siRNA pharmacodynamics in a luciferase-expressing mouse. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] Keith Bowman,et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.
[14] Andrew D. Miller. Cationic Liposomes for Gene Therapy , 1998 .
[15] Theresa A. Storm,et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.
[16] K. G. Rajeev,et al. Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.
[17] L. Medina-Kauwe,et al. Intracellular trafficking of nonviral vectors , 2005, Gene Therapy.
[18] Daniel G. Anderson,et al. Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.
[19] Anton P. McCaffrey,et al. Inhibition of hepatitis B virus in mice by RNA interference , 2003, Nature Biotechnology.
[20] Michael S. Goldberg,et al. Screening, synthesis, and applications of "lipidoids", a novel class of molecules developed for the delivery of RNAi therapeutics , 2008 .
[21] Anton P. McCaffrey,et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.
[22] Daniel G. Anderson,et al. Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] Daniel G Anderson,et al. Electrostatic surface modifications to improve gene delivery , 2010, Expert opinion on drug delivery.
[24] H. Himmelbauer,et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division , 2004, Nature.
[25] Wolfgang A. Weber,et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.
[26] D. Livingston,et al. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. , 2010, Carcinogenesis.
[27] R. Wattiaux,et al. Endosomes, lysosomes: their implication in gene transfer. , 2000, Advanced drug delivery reviews.
[28] R. Langer,et al. Accelerated discovery of synthetic transfection vectors: parallel synthesis and screening of a degradable polymer library. , 2001, Journal of the American Chemical Society.
[29] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[30] Robert Langer,et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.
[31] Matthias John,et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.
[32] F. Szoka,et al. Chloride Accumulation and Swelling in Endosomes Enhances DNA Transfer by Polyamine-DNA Polyplexes* , 2003, Journal of Biological Chemistry.
[33] Douglas S. Conklin,et al. Gene expression: RNA interference in adult mice , 2002, Nature.
[34] Michael S. Goldberg,et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] R. Burger,et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.
[36] J. Behr,et al. Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[37] M. Sioud. Does the understanding of immune activation by RNA predict the design of safe siRNAs? , 2008, Frontiers in bioscience : a journal and virtual library.
[38] P. Sharp,et al. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells , 2010, Proceedings of the National Academy of Sciences.
[39] A. Fire,et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.
[40] M. Bally,et al. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity , 1999, Nature Biotechnology.
[41] L. Palmer,et al. Lipid-based systems for the intracellular delivery of genetic drugs. , 1999, Molecular membrane biology.
[42] Dan Peer,et al. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. , 2010, Biomaterials.
[43] Patrick J. Paddison,et al. A resource for large-scale RNA-interference-based screens in mammals , 2004, Nature.
[44] M. Bally,et al. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. , 1998, Biochimica et biophysica acta.
[45] Claes Wahlestedt,et al. RNA Interference with chemically modified siRNA. , 2006, Current topics in medicinal chemistry.
[46] Robert Langer,et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.
[47] Michael S. Goldberg,et al. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis , 2009, Proceedings of the National Academy of Sciences.
[48] Daniel G. Anderson,et al. Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. , 2010, Bioconjugate chemistry.
[49] J. Rossi,et al. An Aptamer-siRNA Chimera Suppresses HIV-1 Viral Loads and Protects from Helper CD4+ T Cell Decline in Humanized Mice , 2011, Science Translational Medicine.
[50] J. Wolff,et al. Breaking the bonds: non-viral vectors become chemically dynamic. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[51] Reuven Agami,et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway , 2004, Nature.
[52] Kathryn A. Whitehead,et al. Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.
[53] E. Wisse,et al. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer , 2008, Gene Therapy.
[54] A. Lee,et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[55] Todd M. Allen,et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. , 2011, The Journal of clinical investigation.
[56] R. Langer,et al. Lipid‐based nanotherapeutics for siRNA delivery , 2010, Journal of internal medicine.
[57] Daniel G. Anderson,et al. Heme oxygenase-1 is an anti-inflammatory host factor that promotes murine plasmodium liver infection. , 2008, Cell Host and Microbe.
[58] L. Palmer,et al. Stabilized plasmid-lipid particles: construction and characterization , 1999, Gene Therapy.